• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

    9.330 +0.130 (+1.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,013,414
    Open 9.320
    Bid (Size) 9.300 (2)
    Ask (Size) 9.400 (1)
    Prev. Close 9.200
    Today's Range 8.990 - 9.490
    52wk Range 2.315 - 9.490
    Shares Outstanding 61,758,994
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million. 
    Via Benzinga
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +92.8%
    +92.8%
    1 Month
    +45.6%
    +45.6%
    3 Month
    +34.6%
    +34.6%
    6 Month
    +229.7%
    +229.7%
    1 Year
    +159.2%
    +159.2%

    More News

    Read More
    Fulcrum Therapeutics to Present at Upcoming Investor Meetings
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For May 1, 2025
    Via Benzinga
    Small-Cap Stocks: An Undervalued Opportunity in a Cautious Market?
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Curious about the stocks that are showing activity after the closing bell on Monday?
    Via Chartmill
    Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics to Present at Upcoming Medical Meetings
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics to Participate in Upcoming May Conferences
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Uncovering Potential: Fulcrum Therapeutics's Earnings Preview
    Via Benzinga
    Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
    From Fulcrum Therapeutics, Inc.
    Via GlobeNewswire
    Which stocks are moving before the opening bell on Tuesday?
    Via Chartmill

    Frequently Asked Questions

    Is Fulcrum Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Fulcrum Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Fulcrum Therapeutics, Inc. - Common Stock trade on?
    Fulcrum Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock?
    The ticker symbol for Fulcrum Therapeutics, Inc. - Common Stock is FULC on the Nasdaq Stock Market
    What is the current price of Fulcrum Therapeutics, Inc. - Common Stock?
    The current price of Fulcrum Therapeutics, Inc. - Common Stock is 9.330
    When was Fulcrum Therapeutics, Inc. - Common Stock last traded?
    The last trade of Fulcrum Therapeutics, Inc. - Common Stock was at 10/01/25 04:00 PM ET
    What is the market capitalization of Fulcrum Therapeutics, Inc. - Common Stock?
    The market capitalization of Fulcrum Therapeutics, Inc. - Common Stock is 576.21M
    How many shares of Fulcrum Therapeutics, Inc. - Common Stock are outstanding?
    Fulcrum Therapeutics, Inc. - Common Stock has 576M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.